PASG Passage Bio, Inc. - Common Stock
$4,56
Kurs · Aug 19, 2026
Fundamentaldaten per Aug 10, 2026
52W-Spanne
$3–$20
8% of range
Analystenbewertung
BUY
9 analysts
Kursziel
$16
+240% upside
P/E (TTM)
-0.3
ROE
-159.7%
Nettogewinnmarge
—
PASG Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$4.56
Marktkapitalisierung
$15M
P/E (TTM)
-0.3
EPS (TTM)
$-14.35
Umsatz (TTM)
—
Dividendenrendite
—
ROE
-159.7%
Verschuldungsgrad
—
52W-Spanne
$3 – $20
PASG Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
—
EPS
$-14.35
2020-12-31
→
2025-12-31
Freier Cashflow
—
Margen
—
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
PASG
Peer-Median
P/E (TTM)
-0.3
—
P/B (K/B)
0.8
2.0
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
PASG
Peer-Median
ROA
-55.3%
-102.4%
ROE
-159.7%
-150.9%
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
PASG
Peer-Median
Current Ratio (Liquiditätsgrad)
2.1
3.5
Quick Ratio
2.0
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
PASG
Peer-Median
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
PASG
Peer-Median
PASG Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
9 Analysten
- Starker Kauf 2 22,2%
- Kauf 4 44,4%
- Halten 3 33,3%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
2 Analysten · 2026-08-14
Median
$15.50
← Unter allen Zielen
$4.56
Tief
$8.00
Hoch
$23.00
Median-Ziel
$15.50
+239,9%
Mittelwert-Ziel
$15.50
+239,9%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.15%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-2.44 | $-2.70 | 0.26% |
| 31. März 2026 | $-2.16 | $-2.85 | 0.69% |
| 31. Dezember 2025 | $-3.95 | $-2.62 | -1.3% |
| 30. September 2025 | $-2.44 | $-2.86 | 0.42% |
| 30. Juni 2025 | $-2.96 | $-4.13 | 1.2% |
| 31. März 2025 | $-5.00 | $-4.69 | -0.31% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| PASG | $38M | -0.8 | — | — | -159.7% | — |
| BCDA | $13M | — | -87.8% | — | 1660.5% | — |
| SNTI | — | -0.4 | -40.2% | — | — | — |
| INTS | $1M | -0.0 | — | — | -165.1% | — |
| AKTX | $26.17B | — | — | — | -64.1% | — |
| PHIO | $12M | -0.2 | — | — | -57.5% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 12
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| R&D Expense | $23M | $40M | $61M | · | · | · | $3M | |
| SG&A Expense | $20M | $25M | $42M | $49M | $60M | $30M | $7M | |
| Operating Income | $-49M | $-70M | $-108M | $-138M | $-186M | $-113M | $-37M | |
| Interest Income | · | · | · | · | $343.0K | $670.0K | $696.0K | |
| Other Non-op | $4M | $6M | $6M | $2M | · | · | · | |
| Income Tax | $0 | $0 | · | · | · | · | · | |
| Net Income | $-46M | $-65M | $-102M | $-136M | $-185M | $-112M | $-46M | |
| EPS (Basic) | $-14.35 | $-21.04 | $-1.86 | $-2.50 | $-3.48 | $-2.91 | · | |
| EPS (Diluted) | $-14.35 | $-21.04 | $-1.86 | $-2.50 | $-3.48 | $-2.91 | · | |
| Shares (Basic) | 3,172,870 | 3,078,665 | 54,743,490 | 54,429,023 | 53,343,959 | 38,615,967 | · | |
| Shares (Diluted) | 3,172,870 | 3,078,665 | 54,743,490 | 54,429,023 | 53,343,959 | 38,615,967 | · | |
| EBITDA | $-49M | $-67M | $-105M | $-135M | $-184M | $-112M | · |
Bilanz 21
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $46M | $38M | $22M | $35M | $129M | $135M | $159M | |
| Prepaid Expense | $629.0K | $838.0K | $923.0K | $926.0K | $2M | $1M | $156.0K | |
| Current Assets | $48M | $79M | $118M | $197M | $325M | $317M | $166M | |
| PP&E (Net) | $4M | $9M | $15M | $23M | $24M | $3M | $1M | |
| PP&E (Gross) | $8M | $19M | $23M | $28M | $26M | $4M | · | |
| Accum. Depreciation | $4M | $10M | $7M | $5M | $2M | $934.0K | · | |
| Other Non-current Assets | $244.0K | $463.0K | $433.0K | $4M | $6M | $8M | $12M | |
| Total Assets | $62M | $102M | $151M | $244M | $355M | $328M | $179M | |
| Accounts Payable | $1M | $742.0K | $1M | $4M | $9M | $5M | $629.0K | |
| Current Liabilities | $23M | $19M | $16M | $18M | $29M | $21M | $4M | |
| Capital Leases | $20M | $22M | $23M | $24M | · | · | · | |
| Deferred Tax | $3M | $4M | $6M | $8M | $1M | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | $41.0K | $76.0K | |
| Total Liabilities | $44M | $41M | $39M | $42M | $36M | $23M | $4M | |
| Common Stock | · | $6.0K | $5.0K | $5.0K | $5.0K | $4.0K | · | |
| Paid-in Capital | $724M | $720M | $706M | $695M | $675M | $476M | $2M | |
| Retained Earnings | $-705M | $-659M | $-594M | $-492M | $-356M | $-171M | $-59M | |
| AOCI | · | $8.0K | $-43.0K | $-966.0K | $-413.0K | $-12.0K | · | |
| Stockholders' Equity | $19M | $61M | $111M | $201M | $319M | $305M | $-56M | |
| Liabilities + Equity | $62M | $102M | $151M | $244M | $355M | $328M | $179M | |
| Shares Outstanding | 3,182,810 | 3,161,503 | 54,944,130 | 54,614,690 | 54,244,996 | 45,614,807 | 4,293,039 |
Cashflow 11
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $728.0K | $3M | $4M | $4M | $2M | $800.0K | $134.0K | |
| Stock-based Comp | $3M | $6M | $11M | $19M | $33M | $15M | $1M | |
| Other Non-cash | $10M | $8M | $9M | $-5M | $24M | $16M | · | |
| Operating Cash Flow | $-32M | $-48M | $-78M | $-118M | $-127M | $-81M | $-40M | |
| CapEx | · | $34.0K | · | · | · | · | · | |
| Investing Cash Flow | $40M | $55M | $65M | $25M | $-46M | $-172M | $-2M | |
| Stock Issued | · | · | · | · | $166M | $228M | · | |
| Net Stock Activity | · | · | · | · | $166M | $228M | · | |
| Financing Cash Flow | $23.0K | $9M | $135.0K | $-1M | $167M | $229M | $176M | |
| Net Change in Cash | $9M | $16M | $-13M | $-94M | $-6M | $-24M | $134M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · |
Rentabilität 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| ROA | -55.3% | -51.2% | -51.8% | -45.5% | -54.3% | -44.3% | · | |
| ROE | -159.7% | -96.7% | -85.9% | -63.9% | -54.4% | -34.9% | · |
Liquidität & Solvenz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 4.1 | 7.2 | 10.7 | 11.0 | 15.0 | · | |
| Quick Ratio | 2.0 | 1.9 | 1.3 | 1.9 | 4.4 | 6.4 | · |
Bewertung (TTM) 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-46M | $-65M | $-102M | $-136M | $-185M | $-112M | · | |
| Market Cap | $38M | $704M | $1.11B | $1.51B | $6.89B | $23.33B | · | |
| P/E | -0.8 | -0.5 | -10.9 | -11.0 | -36.5 | -175.7 | · | |
| P/B | 2.0 | 11.5 | 10.0 | 7.5 | 21.6 | 76.6 | · | |
| P / Tangible Book | 2.0 | 11.5 | 10.0 | 7.5 | 21.6 | 76.6 | · | |
| P / Cash Flow | -1.2 | -14.7 | -14.2 | -12.8 | -54.3 | -289.7 | · | |
| Earnings Yield | -121.6% | -185.5% | -9.2% | -9.1% | -2.7% | -0.57% | · |
Gewinn- und Verlustrechnung 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $3M | $4M | $5M | $4M | $6M | $8M | $10M | $9M | $10M | $12M | · | · | · | · | · | · | |
| SG&A Expense | $7M | $5M | $5M | $4M | $5M | $6M | $5M | $7M | $7M | $7M | $6M | $8M | $8M | $19M | $11M | $11M | |
| Operating Income | $-8M | $-8M | $-14M | $-9M | $-10M | $-16M | $-14M | $-21M | $-17M | $-18M | $-18M | $-29M | $-25M | $-36M | $-28M | $-28M | |
| Other Non-op | $451.0K | $688.0K | $865.0K | $906.0K | $949.0K | $1M | $2M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | · | · | |
| Net Income | $-8M | $-8M | $-13M | $-8M | $-9M | $-15M | $-13M | $-19M | $-16M | $-17M | $-17M | $-27M | $-24M | $-34M | $-27M | $-27M | |
| EPS (Basic) | $-2.44 | $-2.36 | $-8.70 | $-2.44 | $-2.96 | $-4.87 | $-9.50 | $-6.15 | $-5.09 | $-0.30 | $-0.30 | $-0.49 | $-0.44 | $-0.63 | $-0.49 | $-0.49 | |
| EPS (Diluted) | $-2.44 | $-2.36 | $-8.70 | $-2.44 | $-2.96 | $-4.87 | $-9.50 | $-6.15 | $-5.09 | $-0.30 | $-0.30 | $-0.49 | $-0.44 | $-0.63 | $-0.49 | $-0.49 | |
| Shares (Basic) | 3,208,744 | 3,205,866 | -65,284,764 | 3,178,710 | 3,168,933 | 3,163,914 | -59,505,994 | 3,146,582 | 3,142,537 | 56,295,540 | -109,348,536 | 54,789,410 | 54,683,817 | 54,618,799 | -108,706,991 | 54,473,945 | |
| Shares (Diluted) | 3,208,744 | 3,205,866 | -65,284,764 | 3,178,710 | 3,168,933 | 3,163,914 | -59,505,994 | 3,146,582 | 3,142,537 | 56,295,540 | -109,348,536 | 54,789,410 | 54,683,817 | 54,618,799 | -108,706,991 | 54,473,945 | |
| EBITDA | $-8M | $-8M | · | $-8M | $-10M | $-16M | · | $-20M | $-17M | $-17M | · | $-28M | $-24M | $-35M | · | $-28M |
Bilanz 21
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24M | $33M | $46M | $53M | $58M | $63M | $38M | $32M | $25M | $37M | $22M | $34M | $30M | $33M | $35M | $63M | |
| Prepaid Expense | $768.0K | $682.0K | $629.0K | $2M | $1M | $2M | $838.0K | $1M | $1M | $2M | $923.0K | $1M | $1M | $2M | $926.0K | $2M | |
| Current Assets | $25M | $35M | $48M | $56M | $60M | $67M | $79M | $87M | $95M | $108M | $118M | $136M | $154M | $172M | $197M | $223M | |
| PP&E (Net) | · | $826.0K | $4M | $5M | $5M | $6M | $9M | $10M | $13M | $14M | $15M | $16M | $20M | $22M | $23M | $23M | |
| PP&E (Gross) | · | $3M | $8M | $9M | $9M | $9M | $19M | $19M | $22M | $23M | $23M | $22M | $27M | $28M | $28M | $27M | |
| Accum. Depreciation | · | $2M | $4M | $4M | $4M | $3M | $10M | $9M | $9M | $8M | $7M | $6M | $7M | $6M | $5M | $4M | |
| Other Non-current Assets | · | $244.0K | $244.0K | $270.0K | $270.0K | $274.0K | $463.0K | $463.0K | $516.0K | $662.0K | $433.0K | $433.0K | $433.0K | $433.0K | $4M | $5M | |
| Total Assets | $25M | $36M | $62M | $74M | $79M | $86M | $102M | $112M | $125M | $141M | $151M | $169M | $194M | $213M | $244M | $270M | |
| Accounts Payable | $902.0K | $1M | $1M | $952.0K | $2M | $1M | $742.0K | $1M | $621.0K | $2M | $1M | $3M | $3M | $3M | $4M | $5M | |
| Current Liabilities | $21M | $20M | $23M | $22M | $20M | $18M | $19M | $17M | $12M | $13M | $16M | $20M | $20M | $17M | $18M | $22M | |
| Capital Leases | · | $5M | $20M | $21M | $21M | $21M | $22M | $22M | $22M | $23M | $23M | $23M | $23M | $24M | $24M | $24M | |
| Deferred Tax | · | · | $3M | · | · | · | $4M | · | · | · | $6M | · | · | · | $8M | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | · | · | · | · | · | $2M | · | · | |
| Total Liabilities | $21M | $25M | $44M | $43M | $41M | $39M | $41M | $39M | $35M | $36M | $39M | $43M | $43M | $43M | $42M | $46M | |
| Common Stock | · | · | · | · | · | $6.0K | · | $6.0K | $6.0K | $6.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | |
| Paid-in Capital | $725M | $724M | $724M | $723M | $722M | $721M | $720M | $719M | $718M | $716M | $706M | $704M | $701M | $698M | $695M | $691M | |
| Retained Earnings | $-720M | $-712M | $-705M | $-692M | $-684M | $-675M | $-659M | $-647M | $-627M | $-611M | $-594M | $-578M | $-551M | $-527M | $-492M | $-465M | |
| AOCI | · | · | · | · | · | · | $8.0K | $32.0K | $-67.0K | $-69.0K | $-43.0K | $-192.0K | $-340.0K | $-427.0K | $-966.0K | $-1M | |
| Stockholders' Equity | $4M | $12M | $19M | $31M | $38M | $47M | $61M | $73M | $91M | $105M | $111M | $126M | $150M | $170M | $201M | $224M | |
| Liabilities + Equity | $25M | $36M | $62M | $74M | $79M | $86M | $102M | $112M | $125M | $141M | $151M | $169M | $194M | $213M | $244M | $270M | |
| Shares Outstanding | 3,217,810 | 3,207,810 | 3,182,810 | 3,178,710 | 3,178,710 | 62,148,274 | 3,161,503 | 61,767,286 | 61,754,786 | 61,611,796 | 54,944,130 | 54,812,972 | 54,745,680 | 54,626,690 | 54,614,690 | 54,546,596 |
Cashflow 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $25.0K | $129.0K | $127.0K | $200.0K | $200.0K | $201.0K | $675.0K | $800.0K | $800.0K | $806.0K | $743.0K | $1M | $1M | $978.0K | $996.0K | $900.0K | |
| Stock-based Comp | $525.0K | $556.0K | $609.0K | $611.0K | $923.0K | $858.0K | $1M | $1M | $2M | $2M | $2M | $3M | $4M | $3M | $3M | $3M | |
| Other Non-cash | · | $-6M | · | · | · | $499.0K | · | · | · | $-5M | · | · | · | $8M | · | · | |
| Operating Cash Flow | $-9M | $-13M | $-6M | $-5M | $-6M | $-14M | $-8M | $-7M | $-13M | $-19M | $-20M | $-19M | $-17M | $-22M | $-24M | $-23M | |
| Investing Cash Flow | $0 | $20.0K | $0 | $0 | $585.0K | $40M | $14M | $15M | $1M | $25M | $8M | $22M | $14M | $21M | $-3M | $-5M | |
| Financing Cash Flow | · | · | $9.0K | $0 | · | · | $47.0K | $0 | $85.0K | $9M | $46.0K | $0 | · | · | $-588.0K | $-408.0K | |
| Net Change in Cash | $-9M | $-13M | $-6M | $-5M | $-6M | $26M | $5M | $8M | $-12M | $15M | $-12M | $3M | $-3M | $-1M | $-28M | $-29M |
Rentabilität 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -15.0% | -12.3% | · | -8.3% | -9.2% | -13.6% | · | -13.8% | -10.0% | -9.4% | · | -12.3% | -9.7% | -12.6% | · | -8.1% | |
| ROE | -36.6% | -25.9% | · | -14.9% | -14.6% | -20.3% | · | -19.4% | -13.3% | -12.1% | · | -15.5% | -12.0% | -15.2% | · | -9.1% |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.2 | 1.7 | · | 2.5 | 3.0 | 3.7 | · | 5.1 | 7.7 | 8.4 | · | 6.9 | 7.7 | 10.0 | · | 10.3 | |
| Quick Ratio | 1.2 | 1.7 | · | 2.4 | 2.9 | 3.6 | · | 1.9 | 2.0 | 2.9 | · | 1.7 | 1.5 | 1.9 | · | 2.9 |
Bewertung (TTM) 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-33M | $-40M | · | $-52M | $-60M | $-67M | · | $-79M | $-84M | $-102M | · | $-112M | $-124M | $-143M | · | $-156M | |
| Market Cap | $16M | $25M | · | $26M | $25M | $439M | · | $865M | $981M | $1.66B | · | $721M | $1.03B | $1.05B | · | $1.36B | |
| P/E | -0.5 | -0.6 | · | -0.7 | -0.6 | -0.6 | · | -1.2 | -2.5 | -14.5 | · | -6.4 | -8.2 | -7.3 | · | -8.7 | |
| P/B | 3.5 | 2.1 | · | 0.8 | 0.7 | 9.4 | · | 11.9 | 10.8 | 15.9 | · | 5.7 | 6.8 | 6.1 | · | 6.1 | |
| P / Tangible Book | 3.5 | 2.1 | · | 0.8 | 0.7 | 9.4 | · | 11.9 | 10.8 | 15.9 | · | 5.7 | 6.8 | 6.1 | · | 6.1 | |
| P / Cash Flow | · | -1.9 | · | · | · | -31.7 | · | · | · | -87.9 | · | · | · | -46.6 | · | · | |
| Earnings Yield | -209.0% | -160.9% | · | -146.9% | -180.6% | -167.0% | · | -85.9% | -39.8% | -6.9% | · | -15.6% | -12.2% | -13.8% | · | -11.5% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Nettoergebnis | $-46M | $-65M | $-102M | $-136M | $-185M |
| Verwässerte EPS | $-14.35 | $-21.04 | $-1.86 | $-2.50 | $-3.48 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 2.1 | 4.1 | 7.2 | 10.7 | 11.0 |
| Quick Ratio | 2.0 | 1.9 | 1.3 | 1.9 | 4.4 |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 33 Einreicher · $11.6M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 8 (-4 vs. Vorquartal) | 9 (+3 vs. Vorquartal) | 5 (-1 vs. Vorquartal) | 7 (+5 vs. Vorquartal) | +2.5M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | $4.305.120 | 2.885.712 | 37,04% | Aktien |
| Lynx1 Capital Management LP | $3.287.942 | 673.759 | 28,29% | Aktien |
| New Leaf Venture Partners, L.L.C. | $702.031 | 87.426 | 6,04% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $556.144 | 113.964 | 4,78% | Aktien |
| Balyasny Asset Management L.P. | $522.282 | 107.025 | 4,49% | Aktien |
| Ikarian Capital, LLC | $485.643 | 99.517 | 4,18% | Aktien |
| Yiheng Capital Management, L.P. | $420.153 | 86.097 | 3,61% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $233.713 | 47.892 | 2,01% | Aktien |
| VANGUARD GROUP INC | $207.409 | 17.577 | 1,78% | Aktien |
| Erste Asset Management GmbH | $197.225 | 40.665 | 1,70% | Aktien |
| Verdad Advisers, LP | $149.953 | 30.728 | 1,29% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $144.751 | 29.656 | 1,25% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $138.782 | 28.439 | 1,19% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $83.199 | 17.049 | 0,72% | Aktien |
| DELTEC ASSET MANAGEMENT LLC | $73.200 | 15.000 | 0,63% | Aktien |
| Fiduciary Trust Co | $52.460 | 10.750 | 0,45% | Aktien |
| GTS SECURITIES LLC | $48.800 | 10.000 | 0,42% | Aktien |
| BlackRock, Inc. | $4.748 | 973 | 0,04% | Aktien |
| UBS Group AG | $3.318 | 680 | 0,03% | Aktien |
| Vanguard Global Advisers, LLC | $3.113 | 638 | 0,03% | Aktien |
| BARCLAYS PLC | $1.035 | 212 | 0,01% | Aktien |
| SBI Securities Co., Ltd. | $825 | 169 | 0,01% | Aktien |
| WELLS FARGO & COMPANY/MN | $561 | 115 | 0,00% | Aktien |
| MORGAN STANLEY | $244 | 50 | 0,00% | Aktien |
| ACADIAN ASSET MANAGEMENT LLC | $109 | 22.496 | 0,00% | Aktien |
| JPMORGAN CHASE & CO | $73 | 15 | 0,00% | Aktien |
| OSAIC HOLDINGS, INC. | $73 | 15 | 0,00% | Aktien |
| HRT FINANCIAL LP | $62 | 12.712 | 0,00% | Aktien |
| LRI Investments, LLC | $59 | 12 | 0,00% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $59 | 12 | 0,00% | Aktien |
| HARBOUR INVESTMENTS, INC. | $15 | 3 | 0,00% | Aktien |
| CWM, LLC | $8 | 1 | 0,00% | Aktien |
| TSFG, LLC | $0 | 5 | 0,00% | Aktien |
Unternehmensinsider 25 Insider · 13 Führungskräfte · 11 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| William Chou | President and CEO | 15. März 2023 A | — | 0 | 0 | $0 |
| Bruce A Goldsmith | CEO and President | 27. Mai 2022 A | 15.983 | 0 | 0 | $0 |
| Kathleen Borthwick | SVP, Interim CFO | 31. Dezember 2023 M | 25.936 | 0 | 0 | $0 |
| Simona King | Chief Financial Officer | 28. Juli 2023 M | 23.994 | 0 | 0 | $0 |
| Richard Steven Morris | Chief Financial Officer | 21. Mai 2021 P | 5.454 | 0 | 0 | $0 |
| Jill M. Quigley | Chief Operating Officer | 8. Dezember 2021 M | 368.754 | 0 | 0 | $0 |
| Mark S Forman | Chief Medical Officer | 31. Dezember 2023 M | 45.269 | 0 | 0 | $0 |
| Edgar B. Cale | GC & Corporate Secretary | 31. Dezember 2023 M | 45.995 | 0 | 0 | $0 |
| Alexandros Fotopoulos | Chief Technical Officer | 15. Juni 2023 M | 28.693 | 0 | 0 | $0 |
| Monika Maria Toernsen | Chief Commercial Officer | 15. September 2022 M | 3.319 | 0 | 0 | $0 |
| Eliseo Oreste Salinas | Chief Res. & Develop Officer | 22. März 2021 A | — | 0 | 0 | $0 |
| Gary Romano | Chief Medical Officer | 15. März 2021 M | 0 | 0 | 0 | $0 |
| Stephen P Squinto | Head of Research and Dev | 27. Februar 2020 A | — | 0 | 0 | $0 |
| Dolan Sondhi | Direktor | 27. Juli 2023 A | — | 0 | 0 | $0 |
| Derrell Porter | Direktor | 25. Mai 2023 A | — | 0 | 0 | $0 |
| Sandip Kapadia | Direktor | 25. Mai 2023 A | 0 | 0 | 0 | $0 |
| Thomas Woiwode | Direktor | 25. Mai 2023 A | 933.352 | 0 | 0 | $0 |
| Saqib Islam | Direktor | 25. Mai 2023 A | 5.000 | 0 | 0 | $0 |
| Athena Countouriotis | Direktor | 25. Mai 2023 A | 18.900 | 0 | 0 | $0 |
| Michael E. Kamarck | Direktor | 25. Mai 2023 A | — | 0 | 0 | $0 |
| Patrick J. Heron | Direktor | 3. März 2020 C | 5.009.219 | 0 | 0 | $0 |
| Thomas Richard Kassberg | — | 19. Mai 2026 A | — | 0 | 0 | $0 |
| Maxine Gowen | — | 19. Mai 2026 A | — | 0 | 0 | $0 |
| Liam Ratcliffe | — | 27. Mai 2021 A | 2.800 | 0 | 0 | $0 |
| Tadataka Yamada | — | 27. Mai 2021 A | 656.149 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP, Weston Nichols | 2. Juli 2026 | 21,00% | Erste Einreichung | M&A / Verkauf | SEC |
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VII LLC ×10 Einreichungen | 24. Juli 2025 | 4,25% | Änderung | — | SEC |
| Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC ×4 Einreichungen | 9. August 2024 | — | Erste Einreichung | — | SEC |
| Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C., James N. Topper, Patrick J. Heron ×4 Einreichungen | 15. Juni 2023 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 4 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.